PrimeVax Immuno-Oncology Revenue and Competitors
Estimated Revenue & Valuation
- PrimeVax Immuno-Oncology's estimated annual revenue is currently $930k per year.
- PrimeVax Immuno-Oncology's estimated revenue per employee is $155,000
Employee Data
- PrimeVax Immuno-Oncology has 6 Employees.
- PrimeVax Immuno-Oncology grew their employee count by -40% last year.
PrimeVax Immuno-Oncology's People
| Name | Title | Email/Phone |
|---|---|---|
1 | President and CEO | Reveal Email/Phone |
PrimeVax Immuno-Oncology Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is PrimeVax Immuno-Oncology?
PrimeVax Immuno-Oncology, Inc. is developing the only one-time, one-week cancer treatment. We use a combination of the dengue fever virus and autologous dendritic cells to induce a strong immune response along with personalized tumor targeting.
keywords:N/A
N/A
Total Funding
6
Number of Employees
$930k
Revenue (est)
-40%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in San Francisco
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $0.4M | 6 | -25% | N/A |
#2 | $0.1M | 6 | -25% | $31M |
#3 | $0.1M | 6 | 0% | $22.4M |
#4 | $0.1M | 6 | 0% | $6.8M |
#5 | $0.4M | 6 | N/A | N/A |